NCT02738489 is a Phase 1 clinical trial of SHR-1210 in Advanced Melanoma, sponsored by Jiangsu HengRui Medicine Co., Ltd..

Who is sponsoring NCT02738489?

NCT02738489 is sponsored by Jiangsu HengRui Medicine Co., Ltd..

What drugs are being tested in NCT02738489?

Interventions in NCT02738489: SHR-1210.

What condition does NCT02738489 study?

NCT02738489 studies Advanced Melanoma.

Is NCT02738489 still recruiting?

NCT02738489 is currently completed. Last updated 28 February 2023.

Last reviewed 2023-02-28 · How we verify

NCT02738489

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma

Completed Phase 1 Last updated 28 February 2023

What this trial tests

Phase 1 trial testing SHR-1210 in Advanced Melanoma in 36 participants. Completed in 8 January 2020.

Timeline

13 April 2016

Primary endpoint
8 January 2020

8 January 2020

Quick facts

Lead sponsor	Jiangsu HengRui Medicine Co., Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	13 April 2016
Primary completion	8 January 2020
Estimated completion	8 January 2020
Sites	1 location across China

Drugs / interventions tested

SHR-1210 — full drug profile →

Conditions studied

Advanced Melanoma — all drugs for Advanced Melanoma →

Sponsor

Jiangsu HengRui Medicine Co., Ltd. — full company profile →

Who can join

Adults 18 to 70, any sex, with Advanced Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, single center, non-randomized, dose escalation phase I trial to evaluate safety and tolerability of SHR-1210 (camrelizumab) in patients with advanced melanoma with disease progression after standard treatment, unresectable lesions, or metastases. Between Apr 13, 2016, and Jan 8, 2020, 36 patients were enrolled from Beijing Cancer Hospital.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies.
Tan S, Chen D, Liu K, He M, et al · · 2016 · cited 33× · PMID 27815822 · DOI 10.1007/s13238-016-0337-7
Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials.
Zhou L, Wang X, Chi Z, Sheng X, et al · · 2021 · cited 27× · PMID 34290710 · DOI 10.3389/fimmu.2021.691032
Population pharmacokinetics of the anti-PD-1 antibody camrelizumab in patients with multiple tumor types and model-informed dosing strategy.
Wang CY, Sheng CC, Ma GL, Xu D, et al · · 2021 · cited 12× · PMID 33154554 · DOI 10.1038/s41401-020-00550-y
Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy-<i>Ad hoc</i> Analyses of Pooled Data From Two Clinical Trials.
Bai X, Dai J, Li C, Cui C, et al · · 2021 · cited 11× · PMID 34094921 · DOI 10.3389/fonc.2021.639085
Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study.
Zhou L, Wu X, Chi Z, Si L, et al · · 2022 · cited 7× · PMID 35596181 · DOI 10.1186/s12885-022-09663-5
Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China.
Fang W, Zhao S, Zhang Y, Ma Y, et al · · 2019 · cited 3× · PMID 30819827 · DOI 10.1634/theoncologist.2019-io-s1-s03

Verify or expand the search:

Other trials of SHR-1210

Trials testing the same drug.

NCT05799183 — A SHR-1210 BE Study on Healthy Subjects · Phase 1 · terminated
NCT04533490 — A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · unknown
NCT04680988 — A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer · Phase 2 · completed
NCT04790539 — a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer · Phase 2 · unknown
NCT04506242 — Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer · Phase 2 · unknown

Other recruiting trials for Advanced Melanoma

Currently open trials in the same condition.

NCT07310784 — A Phase II Trial of LM103 in Advanced Melanoma · Phase 2 · recruiting
NCT07099430 — A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma · Phase 1, PHASE2 · recruiting
NCT05629546 — Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on C · Phase 1 · recruiting
NCT06264180 — VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] · Phase 3 · recruiting
NCT06298734 — High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial · NA · recruiting

Other Jiangsu HengRui Medicine Co., Ltd. trials

Trials by the same sponsor.

NCT07252921 — Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation in Adults · Phase 2 · completed
NCT07142850 — A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Bolus and Infusion HR · Phase 1 · completed
NCT07073157 — Effect of HRS-8427 for Injection on the Pharmacokinetics of Furosemide and Metformin in Healthy Subjects。 · Phase 1 · completed
NCT07076459 — A Comparative Pharmacokinetic Study of Single-Dose Administration of HR091506 Tablets From Different Batches in Healthy · Phase 1 · completed
NCT07049107 — Pharmacokinetics Impact of HRS-8427 on Bupropion and Midazolam in Healthy Subjects · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02738489 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jiangsu HengRui Medicine Co., Ltd.
Last refreshed: 28 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02738489.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing